Fulgent Genetics/$FLGT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fulgent Genetics
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Ticker
$FLGT
Sector
Primary listing
Industry
Health Care Providers & Services
Headquarters
Employees
1,313
ISIN
US3596641098
Website
Fulgent Genetics Metrics
BasicAdvanced
$597M
-
-$1.34
1.01
-
Price and volume
Market cap
$597M
Beta
1.01
52-week high
$25.11
52-week low
$14.57
Average daily volume
255K
Financial strength
Current ratio
6.323
Quick ratio
6.08
Long term debt to equity
0.545
Total debt to equity
0.737
Interest coverage (TTM)
-5,136.79%
Profitability
EBITDA (TTM)
-47.731
Gross margin (TTM)
38.80%
Net profit margin (TTM)
-13.94%
Operating margin (TTM)
-24.59%
Effective tax rate (TTM)
15.42%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-3.69%
Return on equity (TTM)
-3.72%
Valuation
Price to revenue (TTM)
2.044
Price to book
0.53
Price to tangible book (TTM)
0.62
Price to free cash flow (TTM)
-18.91
Free cash flow yield (TTM)
-5.29%
Free cash flow per share (TTM)
-103.65%
Growth
Revenue change (TTM)
1.71%
Earnings per share change (TTM)
-75.96%
3-year revenue growth (CAGR)
-32.56%
3-year earnings per share growth (CAGR)
-55.15%
What the Analysts think about Fulgent Genetics
Analyst ratings (Buy, Hold, Sell) for Fulgent Genetics stock.
Bulls say / Bears say
Fulgent Genetics reported adjusted earnings of $0.04 per share for Q1 2025, surpassing analyst expectations of a $0.18 loss, indicating strong financial performance. (reuters.com)
CFO Paul Kim's purchase of 100,000 shares in March 2025 demonstrates strong insider confidence in the company's future prospects. (marketbeat.com)
Raymond James maintained an 'outperform' rating for Fulgent Genetics in May 2025, with a price target of $25, suggesting potential for stock appreciation. (marketbeat.com)
Piper Sandler reduced its price target for Fulgent Genetics from $22.00 to $16.00 in March 2025, indicating concerns about the company's valuation. (marketbeat.com)
The Bank of New York Mellon Corp decreased its holdings in Fulgent Genetics by 20.3% during Q4 2024, potentially signaling reduced institutional confidence. (marketbeat.com)
Fulgent Genetics reported a net loss of $11.53 million for Q1 2025, despite positive adjusted earnings, highlighting ongoing profitability challenges. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Fulgent Genetics Financial Performance
Revenues and expenses
Fulgent Genetics Earnings Performance
Company profitability
Fulgent Genetics News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
GlobeNewsWire·4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Accesswire·2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fulgent Genetics stock?
Fulgent Genetics (FLGT) has a market cap of $597M as of June 27, 2025.
What is the P/E ratio for Fulgent Genetics stock?
The price to earnings (P/E) ratio for Fulgent Genetics (FLGT) stock is 0 as of June 27, 2025.
Does Fulgent Genetics stock pay dividends?
No, Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Fulgent Genetics dividend payment date?
Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulgent Genetics?
Fulgent Genetics (FLGT) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.